Valuation: Cellectar Biosciences, Inc.

Market Cap 20.14M 17.66M 16.28M 15.24M 28.57M 1.9B 29.17M 196M 75.7M 939M 75.62M 73.97M 3.26B P/E 2026 *
-1.23x
P/E 2027 * -1.57x
Enterprise Value 20.14M 17.66M 16.28M 15.24M 28.57M 1.9B 29.17M 196M 75.7M 939M 75.62M 73.97M 3.26B EV / Sales 2026 *
-
EV / Sales 2027 * 2.98x
Free-Float
97.93%
Yield 2026 *
-
Yield 2027 * -
06-01 Cellectar Biosciences Highlights New Efficacy Data from Phase 2B Clover Wam Study of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-19 Cellectar Biosciences Files for Secondary Offering of Common Shares MT
05-18 Cellectar Biosciences, Inc. Announces Board Changes CI
05-14 Cellectar Biosciences, Inc., Q1 2026 Earnings Call, May 14, 2026
05-14 Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-05 Cellectar Biosciences, Inc. announced that it has received $30.708034 million in funding from Balyasny Asset Management L.P., Nantahala Capital Management, LLC, Caligan Partners, LP, Janus Henderson Investors US LLC, Silverarc Capital Management, LLC and other investors CI
05-05 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2B Clover Wam Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-05 Cellectar Biosciences, Inc. Appoints Andrew Gu to Board of Directors CI
04-22 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Chief Financial Officer, Effective as of May 1, 2026 CI
04-22 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Principal Accounting Officer, Effective as of May 1, 2026 CI
04-21 Cellectar Biosciences Announces Subset Of Clover Clinical Trial Data Accepted For Presentation At American Society Of Clinical Oncology Conference CI
04-14 Cellectar Biosciences Enrolls First Patient in Clr 125 Auger-Emitting Radioconjugate Phase 1B Clinical Trial Targeting Refractory Triple Negative Breast Cancer CI
03-04 Cellectar Biosciences, Inc., 2025 Earnings Call, Mar 04, 2026
1 day+2.02%
1 week-9.68%
Current month-19.75%
1 month-19.75%
3 months-6.67%
6 months-1.56%
Current year-14.58%
1 week 2.46
Extreme 2.46
2.88
1 month 2.2
Extreme 2.2
3.26
Current year 2.2
Extreme 2.2
4.7
1 year 2.2
Extreme 2.2
8.05
3 years 2.2
Extreme 2.2
133.5
5 years 2.2
Extreme 2.2
396
10 years 2.2
Extreme 2.2
11,070.01
Manager TitleAgeSince
Chief Executive Officer 66 2015-06-14
Director of Finance/CFO 60 2014-05-27
Chief Operating Officer 52 2022-02-22
Director TitleAgeSince
Director/Board Member 69 2008-01-31
Director/Board Member 66 2015-06-14
Director/Board Member 61 2015-06-14
Date Insider Type Main position Quantity % Market Cap.
05-06Buy

Chief Executive Officer

34,720 1.2970%
05-06Buy

Chief Operating Officer

34,720 1.2970%
12-11Sell

Director

198 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
+2.02%-9.68%-68.10%-95.43% 20.14M
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.59%+6.23%+21.08%+39.55% 361.61B
Weighted average by Cap. +3.85%+8.93%+41.75%+80.17%

Financials

2026 *2027 *
Net sales - 6.76M 5.93M 5.47M 5.12M 9.6M 638M 9.8M 65.72M 25.43M 315M 25.4M 24.85M 1.09B
Net income -30.88M -27.08M -24.96M -23.37M -43.82M -2.91B -44.72M -300M -116M -1.44B -116M -113M -4.99B -34.97M -30.66M -28.26M -26.46M -49.62M -3.3B -50.65M -340M -131M -1.63B -131M -128M -5.65B
Net Debt - -
Logo Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Employees
11
Date Price Change Volume
26-06-26 US$2.520 +2.02% 11,268
26-06-25 US$2.470 -0.80% 78,823
26-06-24 US$2.490 -0.40% 37,354
26-06-23 US$2.500 -2.72% 59,408
26-06-22 US$2.570 -7.89% 96,025
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.520USD
Average target price
10.33USD
Spread / Average Target
+310.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLRB Stock